Invesco Biotechnology & Genome ETF Rating → I’m afraid WWIII is a very real possibility (From Porter & Company) (Ad) Free PBE Stock Alerts $64.60 -0.42 (-0.65%) (As of 05/17/2024 ET) Add Compare Share Share RatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Invesco Biotechnology & Genome ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PBE Aggregate RatingModerate Buy2.68Holdings in PBE have an aggregate rating of Moderate Buy based on 357 analyst ratings issued in the past year covering 30 companies (100.0% of the portfolio).PBE Aggregate Price Target$83.0528.56% UpsideHigh Prediction$109.55Average Prediction$83.05Low Prediction$58.60Holdings in PBE have an aggregate price target of $83.05 and a range of $58.60 to $109.55 covering 30 companies (100.0% of the portfolio).PBE Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy5 Buy rating(s)Moderate Buy21 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Invesco Biotechnology & Genome ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 30 PBE Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.82%TECHBio-Techne$83.81+1.2%4 of 5 stars2.82$80.50 -3.9%11Positive News5.43%AMGNAmgen$312.47-0.7%5 of 5 stars2.52$305.65 -2.2%21Options Volume5.15%REGNRegeneron Pharmaceuticals$982.29+1.5%4 of 5 stars2.76$989.36 0.7%21Analyst ForecastInsider SellingNews CoveragePositive News5.13%BIIBBiogen$230.57+0.2%5 of 5 stars2.65$288.46 25.1%26Analyst ForecastNews CoveragePositive News5.13%NBIXNeurocrine Biosciences$142.29+0.3%5 of 5 stars2.79$148.96 4.7%24Analyst ForecastInsider Selling5.10%VRTXVertex Pharmaceuticals$445.21+1.0%4 of 5 stars2.48$432.18 -2.9%254.68%GILDGilead Sciences$67.72-0.2%5 of 5 stars2.35$83.69 23.6%174.53%BMRNBioMarin Pharmaceutical$77.56+0.8%5 of 5 stars2.60$106.11 36.8%21Analyst ForecastShort Interest ↑Analyst Revision3.57%TGTXTG Therapeutics$16.48-5.4%4 of 5 stars2.83$29.83 81.0%63.36%UTHRUnited Therapeutics$274.26+0.7%5 of 5 stars2.90$308.78 12.6%10Analyst UpgradeInsider Selling3.34%MNKDMannKind$4.593 of 5 stars3.00$8.00 74.3%33.32%PTCTPTC Therapeutics$33.10-2.8%2 of 5 stars1.92$33.67 1.7%133.30%HALOHalozyme Therapeutics$44.71-1.5%5 of 5 stars2.83$53.14 18.9%6Positive News3.23%BPMCBlueprint Medicines$104.96-1.6%1 of 5 stars2.53$102.65 -2.2%17Analyst ForecastShort Interest ↑Analyst Revision3.20%CPRXCatalyst Pharmaceuticals$16.49+0.5%5 of 5 stars3.00$26.71 62.0%52.89%MYGNMyriad Genetics$25.29+2.8%2 of 5 stars2.50$25.57 1.1%8Insider Selling2.84%CLDXCelldex Therapeutics$38.21-4.3%1 of 5 stars2.80$66.00 72.7%5Analyst Forecast2.82%QGENQiagen$45.69-0.7%4 of 5 stars2.56$50.95 11.5%92.81%EXELExelixis$20.91-1.5%5 of 5 stars2.59$26.13 24.9%17Analyst ForecastInsider SellingShort Interest ↑2.73%COLLCollegium Pharmaceutical$32.47-3.6%3 of 5 stars2.20$39.00 20.1%5Insider Selling2.67%VCELVericel$48.35+1.6%1 of 5 stars3.00$46.80 -3.2%6Analyst Upgrade2.45%VCYTVeracyte$22.88-2.2%3 of 5 stars2.60$27.50 20.2%5Positive News2.45%DVAXDynavax Technologies$11.11-1.5%4 of 5 stars2.75$25.33 128.0%4Short Interest ↑Analyst Revision2.45%ITCIIntra-Cellular Therapies$65.00-2.3%5 of 5 stars2.90$90.17 38.7%10Positive News2.38%IONSIonis Pharmaceuticals$37.31-0.8%5 of 5 stars2.71$59.54 59.6%14Short Interest ↓News CoverageGap Down2.28%XENEXenon Pharmaceuticals$39.80-1.3%3 of 5 stars3.00$59.11 48.5%9Options Volume2.23%RGENRepligen$171.94+0.5%4 of 5 stars2.89$197.75 15.0%9Positive News1.80%FOLDAmicus Therapeutics$9.57+0.7%4 of 5 stars2.86$17.50 82.9%7Analyst UpgradeShort Interest ↓1.66%ACADACADIA Pharmaceuticals$14.79-0.4%4 of 5 stars2.75$28.94 95.7%16Short Interest ↑1.20%EYPTEyePoint Pharmaceuticals$11.84-5.4%2 of 5 stars3.00$33.71 184.7%7Insider SellingAnalyst Revision This page (NYSEARCA:PBE) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaWhat’s Really Next for America…Porter & Company[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
